** Shares of biotech firm Mesoblast MSB.AX down 6.5% at A$2.245
** MSB falls as much as 7.1% earlier in the day, hitting its lowest since December 18, 2024
** First day of trading as a constituent of the S&P/ASX 200 benchmark index .AXJO, which is trading 0.7% lower as of 0223 GMT
** Arcadium Lithium ALTM.N, which is being acquired by Rio Tinto RIO.L, RIO.AX, removed from index at start of trading on March 6
** Melbourne-based MSB, which is developing medicines to treat life-threatening inflammatory conditions, top loser in the benchmark index
** MSB's Nasdaq-listed shares MESO.O closed 0.8% higher overnight after a cumulative 14.2% drop in the previous two sessions
** MSB reported HY loss of $47.9 million last week, compared with a $32.5 million loss a year earlier
** MSB shares down 28% this year, following a 10-fold surge last year
(Reporting by Sameer Manekar in Bengaluru)
((Sameer.Manekar@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.